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ABSTRACT 
 
Development Of An Artificial Membrane Lung 
by 
Uditha Piyumindri Fernando 
 
 
Co-chair: Robert H. Bartlett 
Co-chair: Joseph L. Bull 
 
End-stage lung disease due to chronic obstructive pulmonary disease (COPD) is a 
leading cause of death across the world. However, treatment options for end-stage 
COPD are extremely limited. An artificial membrane lung designed to provide 
pulmonary support, primarily by clearance of CO2, is a promising alternative 
treatment for end-stage COPD patients. Current hollow fiber membrane lungs feature 
a predominantly straight blood path length across the fiber bundle, resulting in limited 
oxygen transfer efficiency due to the boundary layer effect. Furthermore, these lungs 
also utilize long gas fibers relative to the blood path length, resulting in a limited CO2 
clearance efficiency due to the build-up of CO2 within the fiber lumens.  
 
 xii	  
Using computational fluid dynamics and optical flow visualization methods, a unique 
hollow fiber membrane lung was designed and created comprising concentric circular 
blood flow paths connected by gates, in addition to a short gas path length, referred to 
as the M-Lung. The M-Lung, comprising a fiber surface area of 0.28 m2 and priming 
volume of 47 mL, has a rated flow of 2 L/min and the oxygenation efficiency is 357 
mL/min/m2. The CO2 clearance of the lung is 200 mL/min at the rated blood flow. 
Given its high gas transfer efficiency, as well as its compact size, low priming 
volume, and propensity for minimal thrombogenecity, this lung design has the 
potential to be used in a range of acute and chronic respiratory support applications, 
including providing CO2 clearance and partial oxygenation in adults with end-stage 
COPD as well as total respiratory support for infants and small children. 
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Chapter 1  
Introduction 
 
Motivations and Objectives 
End-stage lung disease due to chronic obstructive pulmonary disease (COPD) is the 
third leading cause of death in the United States, and affects over 12 million adults 
each year. In addition, COPD inflicts a significant national economic burden, costing 
$50 billion in 2010 in direct and indirect costs(1). COPD is a term that encompasses 
both chronic bronchitis and emphysema. These two diseases are characterized by 
obstruction to airflow that interferes with normal breathing. End-stage COPD, defined 
as Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4: very 
severe(2), is characterized by progressively worsening CO2 retention and concomitant 
dyspnea during activities of daily living, and finally even at rest, resulting in a 
severely diminished quality of life. Concomitantly, the clinical and economic cost of 
COPD increases with the severity of the disease, with end-stage COPD requiring the 
by far largest proportion of health-care resources due to excessive hospitalization, 
exacerbation and mortality rates(3-5). The only currently available curative therapy for 
end-stage COPD is lung transplantation(6-9). The demand for lungs, however, far 
exceeds the donor supply, resulting in long wait-times and ineligibility(8-10); in 2011, 
COPD accounted for over 140,000 deaths, while fewer than 2000 lung transplants 
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were performed in the United States, including transplants for conditions other than 
COPD(11, 12). The median wait time for a lung transplant is 4 months, and over 15% of 
patients die while awaiting a transplant(13). Further, many other patients suffering 
from COPD may not be eligible for transplantation due to comorbidities or functional 
status. Current alternative treatment options for management of COPD are 
pharmacological therapy (primarily bronchodilators and corticosteroids), pulmonary 
rehabilitation, oxygen therapy, ventilator support, and lung volume reduction surgery 
(LVRS)(2). However, these have limited efficacy in end-stage COPD(2), do not address 
CO2 retention, do not improve the quality of life(14), or are contraindicated for patients 
with severely impaired lung function or comorbidities(15, 16). These limitations 
highlight the need for a better alternative treatment option for end-stage COPD that 
addresses stabilization of the chronic disease and prevention of acute exacerbation, 
while allowing the patient to maintain a better quality of life.  
 
Extracorporeal support for oxygenation was first proposed in 1972 by Hill et al.(17), 
and in 1978, Kolobow et al. demonstrated the feasibility of extracorporeal support for 
CO2 removal(18). Traditionally, the extracorporeal circuit is comprised of a membrane 
oxygenator, through which blood is pumped using a mechanical pump, as shown in 
Figure 1.1(19). While this circuit is effective in both oxygenating and removing CO2 
and resolving related symptoms, the use of a mechanical pump necessitates a stay in 
an intensive care unit for the duration of the treatment. In addition to limiting a 
patient’s activity, this exposes the patients to an increased risk of nosocomial 
infections(20, 21). Furthermore, the use of extracorporeal membrane oxygenators carries 
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the risk of complications such as thrombosis and hemolysis(22). These risks effectively 
limit the use of traditional extracorporeal support as a long-term therapy for end-stage 
COPD patients.  
 
 
Figure 1.1: Standard extracorporeal membrane oxygenation circuit (taken from 
Lindstrom SJ, Pellegrino VA, Butt WW. Extracorporeal membrane oxygenation. The 
Medical journal of Australia. 2009;191(3):178-82.) 
 
Coupled with recent advances in low-resistance membrane gas exchange devices, 
recent studies have demonstrated the feasibility of using pumpless extracorporeal CO2 
removal for treatment in acute respiratory distress syndrome (ARDS) or 
exacerbations with acute hypercapnic respiratory failure in COPD patients(23-25). 
However, these pumpless circuits are still cumbersome and utilize oxygenators that 
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have less than optimally efficient performance, which restricts their potential for use 
as a long-term, ambulatory treatment in end-stage COPD. The objective of this study 
was to design a novel artificial lung that could be perfused by a systemic arterio-
venous pressure gradient, to provide pulmonary support, primarily by clearance of 
CO2, as a more effective long-term treatment option in end-stage COPD. 
 
Artificial Membrane Lung Design 
In the native lung, the low PCO2 and high PO2 in the alveolar space relative to adjacent 
capillary blood drives the diffusion of oxygen into blood and CO2 out of blood 
(Figure 1.2A). In normal physiology, these concentration gradients are maintained 
through the process of breathing, referred to as ventilation, which removes the CO2 
build up in the alveolar space and reestablishes the gas concentration gradients. The 
process of exhaling is referred to as ventilation. Analogous to the gas exchange across 
the alveolar/capillary wall in the native human lung, gas exchange in hollow fiber 
membrane lungs is driven by the concentration gradient across the fiber membrane, 
which separates the blood and gas phases (Figure 1.2B).  
 
 
Figure 1.2: Diffusion driven gas exchange: A) across the alveolar/capillary wall in the 
native human lung and B) across the fiber membrane in hollow fiber membrane 
lungs. 
 5	  
In current hollow fiber membrane lungs, the primary blood path is straight flow 
directed across the fiber bundle. Only the red blood cells that are in contact with the 
gas exchange surface of each fiber are oxygenated; this is known as the diffusion 
boundary layer effect.(26) Mixing of the flowing blood to disrupt the boundary layer is 
achieved by the small secondary flows induced as the blood contacts each successive 
fiber.(27) This results in 100-160 mL oxygen exchange per minute per square meter at 
rated flow.(28) The rated flow is the flow of standardized venous blood that leaves the 
membrane lung at 95% oxyhemoglobin saturation. This project investigates the 
design and development of a novel paracorporeal M-Lung from the initial design 
phase through validation of the device in a large animal model. 
 
The induction of secondary flows in a circular chamber, which could decrease the 
diffusion boundary layer effect, ultimately reaching the diffusion limit of the PDMS 
(silicone rubber) membrane, was described previously by Bartlett et al. and Drinker et 
al.(29-31) Blood was simulated by rapidly moving the membrane surface of the circular 
chamber against static or slowly flowing blood.  A membrane lung using flat sheet 
PDMS formed into concentric circular chambers connected by gates, which reached 
membrane limitation for oxygen diffusion for PDMS. Secondary flows were created 
by mechanical oscillation of the device.  The oxygen transfer efficiency was 205 
mL/min/m2 for a 5 mm PDMS membrane. The fabrication problems and noise made 
the design impractical for clinical use, but demonstrated that oxygen transfer 
efficiency is based on the extent of secondary flows. 
 
 6	  
Similar secondary flows are generated when blood flows through a static circular 
chamber with a curved flow path.(32, 33) The higher the flow, the more intense the 
secondary flow vortices formed. Therefore, we hypothesized that a membrane lung 
with concentric circular blood flow paths connected by gates would have high 
oxygenation efficiency created by secondary flows inherent in the design.  
 
The physiological mechanism of CO2 removal is distinct from that of oxygenation 
and therefore feature distinct optimal design criteria. While oxygenation is limited 
primarily by diffusion, CO2 is limited primarily by ventilation. Hence, a key criterion 
of a lung designed for optimal CO2 removal should be optimal ventilation. Clinically, 
CO2 in enhanced by increasing the ventilation flow rate. However, the risk of fatal air 
emboli poses an upper limit to the ventilation flow rate.  A more robust way of 
enhancing CO2 ventilation is by maintaining short gas fibers. We therefore 
hypothesized that a membrane lung featuring short fibers (as opposed to fewer longer 
fibers) would have a high CO2 removal efficiency as a result of minimizing CO2 
build-up in the gas phase. Based on these hypotheses, we designed a novel membrane 
lung, referred to as the M-Lung. 
 
The M-Lung Design 
The M-Lung design is shown in Figure 1.3. The device has an outer shell comprising 
a blood inlet port, blood outlet port, gas inlet port, and gas outlet port (Figure 1.3AΦ). 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Φ	  A full International Patent Application has been filed for the M-Lung design on behalf of the Regents 
of the University of Michigan through the University of Michigan Technology Transfer Office by 
Harness, Dickey & Pierce, P.L.C. The inventors listed are Robert H. Bartlett, Joseph L. Bull, and 
Uditha Piyumindri Fernando. 
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Figure 1.3: M-Lung design. Cross sectional views of the assembled device (A) is 
shown in B and C. The colored arrows indicate the concentration levels of O2 and 
CO2 in blood: red indicates blood with high O2 and low CO2 concentrations, while 
blue indicates blood with low O2 and high CO2 concentrations. 
 
Blood with low O2 and high CO2 concentrations (systemic venous blood) enters the 
blood inlet port lumen, and blood with high O2 and low CO2 concentrations exits the 
M-Lung through the blood outlet port. Air with high O2 and low CO2 concentrations 
is introduced in via gas inlet port and a mixture of low O2 and high CO2 
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concentrations exits the M-Lung via gas outlet port lumen, as shown in Figure 
1.3A,C. As shown in Figure 1.3B, the oxygenator outer shell encloses a fiber bundle 
and a number of circular dividers radially separating the fiber bundle. Each divider 
has a single gate opening, allowing the blood to flow through the fiber bundle 
compartments; the blood from the blood inlet port flows through the fiber bundle 
compartments into the lumen of the blood outlet port. The fiber bundle (Figure 1B,C) 
comprises an array of micro-porous hollow fibers having the upper and lower ends 
potted, so that the lumens of the fibers communicate with plenum between the gas 
ports and the fiber bundle. The fiber bundle is wound around the innermost divider 
such that the cross section of each fiber is parallel to the cross-sectional plane in 
Figure 1.3B.   
 
Summary Of The Study 
The goal of this work was to design and build a novel, highly efficient, and compact 
artificial lung that could be perfused by the heart (via systemic arterio-venous 
pressure gradient), which had the potential to serve as a more effective long-term 
treatment option in end-stage COPD. Computational and experimental methods were 
used to develop the lung from the initial design phase through validation of the device 
in vitro. First, the design concept is developed and the underlying fluid dynamics is 
investigated both theoretically and experimentally. Next, we the functional 
performance of the M-Lung is tested in vitro. Finally, the functional efficiency of the 
M-Lung is compared to similarly sized commercial oxygenators.  
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Chapter 2 
M-Lung Design 
 
Introduction 
In Chapter 1, the basis for the M-Lung design is described; it was hypothesized that a 
membrane lung with concentric circular blood flow paths connected by gates would 
have high oxygenation efficiency created by secondary flows inherent in the design, 
while a membrane lung featuring short fibers would have a high CO2 removal 
efficiency as a result of minimizing CO2 build-up in the gas phase. In this chapter, the 
flow dynamics within the M-Lung is evaluated using both computational and optical 
visualization methods to understand the effect of design parameters on flow dynamics 
and optimize the design of the M-Lung.   ` 
 
Methods 
Computational Fluid Dynamics 
In order to evaluate and optimize flow patterns through the M-Lung housing, the flow 
through the M-Lung housing was simulated both with and without the fiber bundle, 
for a variety of models with varying gate widths, numbers of gates, and placements, 
and inlet flow rates. The following parameters were evaluated: velocity, vorticity, 
pressure drop, resistance, shear stress, circulation, fiber surface area, and priming 
volume. SolidWorks (Dassault Systèmes SolidWorks Corp., Concord, MA) and Creo 
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(PTC Inc., Needham, MA) computer-aided design (CAD) software was used to create 
each model, which was then imported into the COMSOL Multiphysics (COMSOL 
AB, Stockholm, Sweden) CFD software program. Blood was modeled as an 
incompressible Newtonian fluid governed by equations 1-2. 
 ρ u ∙ ∇ u = ∇ ∙ −pI+ µμ ∇u+ ∇u !  (1) ρ∇ ∙ u = 0 (2) 
 
Where µμ denotes the dynamic viscosity (Pa·s), u denotes the velocity (m/s), ρ is the 
fluid’s density (kg/m3), and p is the pressure (Pa). For blood, ρ and µμ were set to be 
1060 kg/m3 and 0.003 Pa s, respectively. The boundary conditions were set as 
follows: wall = no slip, inlet = pulsatile flow (frequency = 1 Hz, amplitude = 2 x 
average flow rate [1.3 L/min and 3 L/min], waveform = sinusoidal, as shown in 
Figure 2.1), and outlet = atmospheric pressure.  
 
 
Figure 2.1: Inlet boundary conditions for CFD. The inlet (blue) and outlet (red) 
boundaries are shown in A, and the pulsatile flow at the inlet for an average flow of 3 
L/min is illustrated in B. 
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A finite element formulation based on the Galerkin method was used to solve for the 
governing equations. The convergence criterion was set to be a relative tolerance of 
0.001 and 0.01 for stationary and time-dependent solutions, respectively. The 
velocity, vorticity, and pressure of the flow are found directly using the software, 
while resistance, shear stress, and circulation are calculated as given in Eq. 3-5, where r denotes resistance (Ω), Q denotes volumetric flow rate (m3/s), τ denotes shear stress 
(Pa), γ denotes shear rate (1/s), C denotes circulation, and ν denotes vorticity (1/s): 
 
r = ∆pQ  (3) τ = µμγ (4) 
C = ν   dS (5) 
 
In addition, the hollow membrane fiber bundle was incorporated into our model as a 
porous media, governed by Darcy’s law with the Brinkman and Forchheimer 
extensions, shown in Eq. 6-9. (1, 2)  The Brinkman extension accounts for momentum 
transport by macroscopic viscous effects as well as pressure gradients, while the 
Forchheimer extension accounts for the turbulent contribution to the resistance to 
flow in the porous domain.  
 µμκ u = ∇ ∙ −pI+ µμϵ! ∇u+ ∇u ! − β! u u (6) ∇ ∙ u = 0 (7) 
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Where κ denotes the permeability of the porous medium (m2), ϵP is the porosity 
(dimensionless), and βF, the Forchheimer coefficient, is given by Eq. 9, where CF is 
the dimensionless friction coefficient (Eq. 8). 
 
C! = 1.75150ϵ!! (8) 
β! = ρϵ!C!κ  (9) 
 
The effects of varying the fiber bundle density were studied by varying the 
permeability of the porous medium. The permeability and porosity of the fiber bundle 
region is related to the total fiber surface area, A!"#$% (m2), as shown in Eq. 10-12(3-5): 
 
κ = ϵ!!d!"#!150(1− ϵ!)! (10) 
ϵ! = 1− N!"#$%d!"#!D!!−D!!  (11) A!"#$% = πd!"#HN!"#$% (12) 
    
Where d!"# denotes the fiber membrane outer diameter (m), N!"#$% is total number of 
fibers, D! and D! are the inner and outer diameter of each fiber bundle, and H is the 
height of the fibers.  
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Particle Image Velocimetry 
In order to verify simulated flow patterns through the M-Lung housing, optical 
visualization of flow patterns through the M-Lung were carried out using particle 
image velocimetry (PIV). The experimental setup is shown in Figure 2.2.  
 
 
Figure 2.2: Particle image velocimetry setup. The grey arrows indicate the laser path, 
which originates from the laser source, is shaped into a laser sheet through a 
cylindrical lens, and illuminates a slice of the M-Lung device. 
 
The M-Lung prototype comprised a poly(methyl methacrelate) (PMMA) housing.  
De-ionized water was used as the model fluid to represent the blood in these 
experiments, since it provided sufficient optical clarity for the particle velocimetry 
measurements described below. Fluid through the M-Lung was pumped using a 
peristaltic pump set to flow rates of 1.5 L/min and 3.0 L/min to match the inlet flow 
rates used in CFD simulations. The water was seeded with neutrally buoyant micro-
porous round polyamide seeding particles (diameter = 20 µm, density = 1.03 g/m3, 
Dantec Dynamics Co., Skovlunde, Denmark). These particles were illuminated by a 
pulsed Nd-YAG laser light (Model: Solo III 15Hz, No: 16155, wavelength 532 nm, 
New Wave Inc., Fremont, CA, U.S.) as shown in Figure 3.2. The laser’s beam passed 
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through a cylindrical lens (Modular Focus, f=-6mm, Rodenstock Co., Munich, 
Germany) and then shaped into a laser light sheet (<1 mm thickness and 100 mm in 
width) that illuminated the area of interest. The images were captured by a CCD 
camera (Flowmaster 3S. resolution: 1280x1024 pixels, LaVision Inc., Goettingen, 
Germany), which was positioned as shown in Figure 2.2. Successive pairs of single 
exposed images were then processed employing PIV software (Davis 6.2, LaVision 
Inc., Goettingen, Germany). Each of the images was divided into small interrogation 
areas of 32x32 pixels, and was cross-correlated with each other with a 50% overlap. 
A time sequence of the velocity field was obtained by capturing successive pairs of 
images and repeating the image cross correlations. The experimental velocity field 
images were then compared with previously obtained computational velocity fields 
through the M-Lung housing (without fibers).  
 
Results 
Computational Fluid Dynamics 
The CFD results, as shown in Figure 2.3, show a well-distributed blood flow profile 
through the device with minimal regions of low blood flow and demonstrate the 
formation of transient flow vortices through the M-Lung housing. The resulting flows 
predict that increasing the flow rate at the inlet increases the mixing, pressure drop, 
and resistance across the device. Furthermore, increasing the number of gates also 
results in an increased velocity (since the effective flow path is elongated), mixing, 
pressure drop, and resistance across the device. 
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Figure 2.3: Varying number of gates and inlet flow rate. (A) illustrates flow patterns 
at t = 4.75 s for an inlet flow rate of 1.5 L/min (I-III) and 3 L/min (IV-VI), with 3 
gates (I,IV), 4 gates (II,V), and 5 gates (III,VI), and the corresponding velocity 
streamlines shown by the yellow lines. (B) shows the corresponding velocity (B1), 
vorticity (B2), pressure drop (B3), and resistance (B4), averaged across 5 seconds. 
 
Next, the fiber bundle was incorporated into the 3-gate model and varied gate width 
(the width of each gate is the distance between the edges of the opening arc of divider 
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placed at a given radial distance). The resulting flow dynamics show that increasing 
the gate width increases the shear stress (Figure 2.4A) and circulation (Fig. 2.4B) 
across the device.  
 
 
Figure 2.4: Computational flow dynamics for varying gate width. The maximum 
shear stress (A) and circulation (B) averaged across 5 seconds is shown as a function 
of gate opening width; the fiber bundle permeability (k) = 2.8e-5 m2. 
 
Thereafter, we studied the effects of varying permeability of the porous media, which 
relates to the fiber bundle packing density and fiber surface area as given in Eq. 5-7. 
The resulting flow patterns (Figure 2.5A) show that the vortices formed in the M-
Lung housing are dampened by the membrane fiber bundle, with the magnitude of 
dampening dependent on the permeability of the membrane fiber bundle (Figure 
2.5B); decreasing the permeability increases the mixing, shear stress (Figure 2.5B,D), 
and circulation (Figure 2.5C,D) across the device, while decreasing the shear stress 
and vorticity at the gates (Figure 2.5D).  
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Figure 2.5: Computational flow patterns for varying fiber bundle permeability. (A) 
shows the velocity profiles obtained at t = 4.75 s for varying fiber bundle 
permeability (k). The yellow lines denote velocity streamlines. The maximum shear 
stress (B) and circulation (C) averaged across 5 seconds is shown as a function of 
permeability. 
 
The permeability of the fiber bundle can be modulated in the fabrication process by 
varying the number of fibers/cm and/or the spacing between each layer of fibers. The 
relationship between fiber bundle permeability and simulated M-Lung pressure drop, 
priming volume, and fiber surface area is shown in Figure 2.6A-C. The simulations 
demonstrate that a significant reduction in the pressure drop across the M-Lung could 
be achieved increasing the fiber bundle permeability (Figure 2.6A), at the cost of an 
increased priming volume (Figure 2.6B) and reduced fiber surface area (Figure 2.6A).  
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Figure 2.6: Simulated effects of varying fiber bundle permeability on M-Lung 
pressure drop for Qb = 0.5 L/min (A), priming volume (B), and fiber surface area (C). 
 
Particle Image Velocimetry 
A comparison of the flow through the M-Lung obtained using simulations and optical 
flow visualization is shown in Figure 2.7. The PIV results demonstrate similar flow 
patterns to those obtained computationally; we observe transient vortices forming 
immediately both experimentally (Figure 2.7A) and computationally (Figure 2.7B) 
after the fluid passes through the gate of the concentric divider. 
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Figure 2.7: Comparison of simulated and experimental flow through the M-Lung 
housing. The experimental PIV results (A) demonstrate similar flow patterns to those 
obtained computationally (B). 
 
Discussion 
The CFD results show a well-distributed blood flow profile through the M-Lung with 
minimal regions of low blood flow. The results also demonstrate the formation of 
transient flow vortices through the M-Lung housing, suggesting that the gated design 
promotes passive secondary flow mixing. Experiemental PIV results demonstrate a 
similar vortex pattern to those obtained computationally. While increasing the 
number of gates results in a longer effective blood path and increase in mixing, the 
resulting increase in resistance poses an upper limit to the number of gates that could 
be supported by systemic arterio-venous perfusion.  
 
The mixing within the M-Lung housing is dampened by the membrane fiber bundle, 
with the magnitude of dampening dependent on the permeability of the membrane 
fiber bundle. The simulations demonstrate that an increase in secondary flow mixing 
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and a significant reduction in the pressure drop across the M-Lung could be achieved 
by increasing the fiber bundle permeability, at the cost of an increased priming 
volume and reduced fiber surface area.  
 
The specific pattern of secondary flows generated depends on a variety of factors, 
including inlet flow rate and pulsatility and specific configuration of dividers and 
gates. Since the inlet flow rate and pulsatility are dependent on the perfusion system 
(pump or native circulation) variations of this design will incorporate a variety of 
divider and gate configurations to meet flow requirements.  
 
In conclusion, using CFD and optical flow visualization methods, a unique hollow 
fiber membrane lung with passive secondary flow generation based on concentric 
circular blood flow paths connected by gates was designed and optimized. In 
prototype testing, flow patterns across the M-Lung matched those predicted by CFD. 
In the next chapter, a functional prototype of the optimal M-Lung design is built 
based on these simulations, and its performance is evaluated in vitro. 
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Chapter 3 
Membrane Lung Fabrication and Performance 
 
 
Introduction 
In Chapter 2, the flow dynamics within the M-Lung was evaluated using both 
computational and optical visualization methods and optimized the design of the M-
Lung. In this chapter, functional prototypes of the M-Lung are built based on the 
optimized design and evaluated the functional performance of the M-Lung in vitro. 
The performance of the M-Lung is then compared to similarly sized commercial 
oxygenators in order to test our hypothesis that the unique M-Lung design comprising 
a concentric circular blood path and short gas path relative to blood path results in an 
increased efficiency of both oxygenation and CO2 clearance.    
 
Methods 
A schematic of the CFD-optimized M-Lung is shown in Figure 3.1. The device has an 
outer shell comprising a blood inlet, blood outlet, gas inlet, and gas outlet ports, as 
shown in Figure 3.1A. This outer shell encloses a fiber bundle separated into 
compartments radially by concentric, circular dividers. Each divider has a gate 
opening, allowing the blood to flow through the fiber bundle compartments; the blood 
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from the blood inlet port flows through the fiber bundle compartments into the lumen 
of the blood outlet port. The fiber bundle comprises an array of micro-porous hollow 
fibers having the upper and lower ends potted, so that the interior lumens of the fibers 
communicate with plenum between the gas ports and the fiber bundle. The fiber 
bundle is wound around the concentric dividers such that the main direction of blood 
flow is perpendicular to direction of gas flow (Figure 3.1B).  
 
 
Figure 3.1: M-Lung design. Cross sectional views of the assembled device are shown 
in A and B. The black and white arrows indicate the main direction of blood flow and 
gas flow, respectively.  
 
 29	  
The specifications for the lung design were as follows: a rated flow ≥1 L/min, oxygen 
transfer at rated flow ≥50 mL/min, pressure drop at rated flow of 60 mmHg, and CO2 
clearance that is four times oxygen transfer. The specifications were chosen based on 
characteristics of existing commercial pediatric size membrane lungs for direct 
comparison among devices.  Furthermore, a membrane lung with these specifications 
would provide total gas exchange for a 10 kg child and total systemic CO2 removal 
for an adult. The following parameters were evaluated: rated flow, surface area, 
oxygen transfer efficiency, priming volume, pressure drop, and CO2 clearance.  
 
Prototype Fabrication 
In order to evaluate the blood gas-exchange performance of the M-Lung, functional 
prototypes, shown in Figure 3.2, were fabricated as follows: The M-Lung housing 
was manufactured using stereolithography (Objet Eden 350v, material: photopolymer 
“Full Cure 720”), and the fiber bundle comprised a cross-wound mat (Figure 3.2A) of 
hollow micro-porous polypropylene (PP) membrane fibers (Membrana GmbH, 
Wuppertal, Germany) with 17 fibers/cm, resulting in a fiber bundle porosity of 0.63, 
fiber surface area of 0.28 m2, fiber length of 2 cm, and priming volume of 47 mL. An 
in-house built centrifuge was used for potting each end of the M-Lung; the M-Lung 
housing, with with the wound fiber bundles and gates in place, were centrifuged at a 
speed of 800 RPM and temperature of 500C for 1 hour, following which the potted 
devices were allowed to cure at 500C for 24 hours. As potting material, a 
biocompatible, addition-curing silicone rubber (Wacker Chemie AG, Munich, 
Germany) was utilized, as shown in Figure 3.2B, C.  
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Figure 3.2: Manufacturing functional M-Lung prototypes. (A) shows the fiber mat 
wound with the divider in place, while (B) shows the assembled device. A zoomed-in 
view of the patent potted fibers is given in (C). The blue regions in (B) and (C) 
indicates the potting material.  
 
In vitro Testing  
The functional performance of the M-Lung was evaluated in vitro in accordance with 
the Food and Drug Administration Guidance for Cardiopulmonary Bypass 
Oxygenators 510(k) guidelines(1) using a test circuit as shown in Figure 3.3. Fresh 
bovine blood was anti-coagulated with heparin to obtain an activated clotting time 
(ACT) > 480 s and filtered through a 70-120 µm screen filter into a clean carboy.  
The circuit was primed and de-aired using a 0.9% sodium chloride (saline) solution, 
which was displaced by filtered blood from the filtration reservoir. The circuit total 
hemoglobin was measured and adjusted with saline solution to 12 ± 1 g/dL. Gas lines 
from the three gas flow controllers (O2, N2, and CO2) were connected to the 
conditioning device (Novalung iLA, Xenios AG, Heilbronn, Germany), and the 
overall gas mixture was controlled by controlling the flow rate of these individual 
gases during the conditioning process.  A flow probe (Transonic, Ithaca, NY) was 
used to monitor and control the blood flow rate through the circuit, while pressure 
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transducers were connected to the blood inlet and blood outlet sites of the test device 
to monitor the pressure drop across the M-Lung.  A heat exchanger connected to the 
circuit was used to warm circuit blood to 37 ± 1 ºC. The blood was pumped and 
recirculated through the conditioning device until the blood pool reached venous 
conditions, as outlined in Table 3.1.  The conditioned blood flow was then directed to 
the test device alone, and the outflow of the test device was directed to the second 
carboy, comprising a single pass test. The test device was ventilated using a sweep 
gas comprised of 100% O2.  
 
 
Figure 3.3: In vitro test circuit schematic. During the conditioning process, the test 
device is isolated from the circuit using clamps at the points denoted by arrows A1 
and A2. During the testing process, the blood is directed through the test device alone 
and into a separate collection carboy using clamps at points denoted by arrows A2, 
B1, and B2, thereby comprising a single-pass test circuit. 
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Table 3.1: Blood Target Specifications 
 
The performance of the M-Lung was evaluated over a range of inlet blood flow rate 
(Qb) and sweep gas flow rates (Qg). For each combination of Qb and Qg, a blood inlet, 
blood outlet, and gas outlet sample were obtained, and the inlet and outlet blood 
pressures were recorded. Between test intervals, the test device was flushed with 
100% O2 to prevent water condensation in the gas phase compartment of the test 
device. All samples were analyzed using a blood gas analyzer (ABL 800 Flex, 
Radiometer, Copenhagen, Denmark). The rated flow was determined as the 
maximum flow at which the test device outlet hemoglobin O2 saturation was ≥95%. 
The O2 transfer rate (VO!, mL/min) at rated flow was calculated as shown in Eq. 13-
15(2, 3): 
 
C!"# = 13.4 ∙ tHb ∙%SAT100 + 0.0314 ∙ pO! (13) pO! = -­‐19.7%SAT  100 -­‐1.21  (14) 
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VO! = Q! ∙ [C!"#-­‐!"#$-­‐C!"#-­‐!"#] (15) 
 
Where C!"#  = O2 concentration in blood (mLO2 Lblood-1), tHb  = hemoglobin 
concentration (g dL-1), %SAT = hemoglobin O2 saturation (%), Q! = blood flow rate 
(L/min); C!"#-­‐!"#$= post-oxygenator O2 concentration (mLO2 Lblood-1), and C!"#-­‐!"#= 
pre-oxygenator O2 concentration (mLO2 Lblood-1). The CO2 transfer rate (VCO! , 
mL/min) was calculated as given in Eq. 16: 
 VCO! = ∆CO! ∙ Q! ∙ 1000 (16) 
 
Where ∆CO! = % CO2 in the outlet gas sample and Q! = sweep gas flow rate (L/min).  
The error bars denote the standard error of mean for each measurement. 
 
Comparison to Commercial Devices  
In order to compare the oxygen transfer efficiency of the M-Lung to similarly sized 
commercial devices, the following commercially available devices were used:  
Capiox RX05 (Terumo Corporation, Tokyo, Japan), Maquet Quadrox-i Neonatal 
(Gettinge Group, Rastatt, Germany), Maquet Quadrox-i Pediatric (Gettinge Group, 
Rastatt, Germany), Medos Hilite 1000 (Xenios AG, Heilbronn, Germany), Medos 
Hilite 2800 (Xenios AG, Heilbronn, Germany), Dideco D100 (Sorin Group, Milan, 
Italy), and Dideco D101 (Sorin Group, Milan, Italy). We obtained the maximum or 
rated flow (Q!"#$%) and fiber surface area (A!"#$%) from the manufacturer manual for 
each of the commercial devices. The O2 transfer at rated flow (VO!-­‐!"#$%) in mL/min 
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was calculated using Equations 13 and 14, and the subsequent O2 transfer efficiency 
(∈!" ) in mL/min/m2 was calculated as given in Equation 17 for each device, 
including the M-Lung. 
 
∈!"= VO!-­‐!"#$%A!"#$%  (17) 
  
CO2 removal is dependent on the Q!  to Q!  ratio. However, different 
manufacturers report CO2 removal data for varying Q! to Q! ratios. In order to 
obtain comparable CO2 removal data and thereby compare the CO2 transfer 
efficiency of the M-Lung to similarly sized commercial devices, the CO2 
removal of each of the following commercially available devices was tested in 
vitro using the same methods as described in the previous section for the M-
Lung: Capiox RX05 (Terumo Corporation, Tokyo, Japan), Medos Hilite 2800 
(Xenios AG, Heilbronn, Germany), Maquet Quadrox-i Pediatric (Gettinge 
Group, Rastatt, Germany), and Novalung iLA (Xenios AG, Heilbronn, 
Germany). The CO2 transfer efficiency (∈!"#) for each device, including the 
M-Lung, was calculated for each Q! to Q! ratio as given in Equation 18. 
 
∈!"#= VCO!A!"#$% (18) 
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Results 
M-Lung Performance 
In in vitro studies, the M-Lung comprising a fiber bundle surface area of 0.28 m2 and 
priming volume of 47 ml (Figure 3.4), maintained a post device oxyhemoglobin level 
≥95% up to a blood flow rate of 2.0 L/min, thereby demonstrating a rated flow of 2.0 
L/min (Figure 3.5). Further, the device was able to remove 200 mL/min of CO2 at the 
rated blood flow rate, using a sweep gas of 16.0 L/min (Figure 3.6).  The blood-side 
pressure drop across the M-Lung comprising a fiber bundle of porosity = 0.63 was 49 
and 106 mmHg at blood flow rates of 1.0 and 2.0 L/min, respectively (Figure 3.7). 
 
 
Figure 3.4: The M-Lung connected to the in vitro test circuit.  
 
 36	  
 
Figure 3.5: M-Lung in vitro oxygenation performance. The M-Lung has a rated flow 
of 2.0 L/min.  
 
 
Figure 3.6: M-Lung in vitro CO2 transfer performance. The M-Lung demonstrates a 
CO2 clearance of 200 mL/min at the rated blood flow with a sweep gas flow rate of 
16 L/min. 
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Figure 3.7. M-Lung in vitro pressure drop. The M-Lung demonstrates a pressure drop 
of 49 mmHg at 1.0 L/min with a fiber bundle porosity of 0.63. 
 
Comparison to Commercial Devices 
A comparison of the oxygenation transfer efficiency of the M-Lung to similarly sized 
commercially available devices is given in Table 3.2. The M-Lung has an oxygen 
transfer efficiency of 357 mL/min/m2, which is the highest oxygen transfer efficiency 
of all evaluated commercial devices by ≥153 mL/min/m2. A comparison of the CO2 
transfer efficiency of the M-Lung to similarly sized commercially available devices is 
given in Figure 3.7A-C. The M-Lung demonstrates one of the highest CO2 transfer 
efficiencies for each of the Q!  to Q!  ratios, achieving ≥200% the CO2 transfer 
efficiency of the Novalung iLA at each Q! to Q! ratio. 
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Figure 3.8: Comparison of CO2 transfer similar size membrane lungs: A) for a Q! to Q! ratio of 1:1, B) for a Q! to Q! ratio of 4:1, and C) for a Q! to Q! ratio of 8:1. The 
Novalung iLA device has a fiber surface area of 1.3 m2 and priming volume of 175 
mL, as reported in the manufacturer manual. 
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Discussion 
The key to maximize oxygen transfer per surface area in membrane lungs is mixing, 
and thereby disrupting the diffusion boundary layer, through an increase in vorticity 
and secondary flows.(4) Flow through circular paths will induce secondary flows to 
create mixing, yet a long circular spiral has high resistance. Concentric circles 
connected by gates created secondary flows without increasing resistance.  The effect 
of the mixing is shown in Table 2. The oxygen transfer efficiency (mLO2/m2 min-1) of 
the M-Lung prototype is 357 mLO2/m2 min-1.  The oxygen transfer efficiency of 
similar devices with predominantly straight flow path is 128-204 mLO2/m2 min-1.  
 
In vitro studies demonstrate highly efficient gas exchange within the M-Lung: the 
device was able to maintain an oxygen saturation of ≥95% for blood flow rates up to 
2.0 L/min with a fiber bundle surface area of 0.28 m2 and priming volume of 47 ml. 
Further, the device was able to remove >180 mL/min of CO2 at the rated flow. The 
CO2 clearance is largely dependent on the sweep gas flow rate to blood flow rate ratio 
and can be further increased by increasing the sweep gas flow. The relatively short 
gas exchange fibers allow the M-Lung to maintain a sufficiently low gas side pressure 
drop at higher sweep flows and minimize water accumulation in gas phase, thereby 
enhancing the CO2 removal efficiency/capacity of the device.  
 
In comparison with similarly sized commercial devices, the M-Lung uniquely 
maintains one of the highest efficiencies for both oxygen and CO2 transfer, 
demonstrating the effect of optimizing the lung design for overcoming both the 
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diffusion-limitation in oxygen transfer by means of secondary flow mixing and 
ventilation limitation in CO2 transfer by means of a relatively short gas path length.   
 
Despite its low priming volume and efficient gas exchange, the M-Lung maintains a 
sufficiently low blood-side pressure drop across the relevant range of blood flow 
rates. At a blood flow rate of 1.0 L/min, the M-Lung had a blood-side pressure drop 
<50 mmHg, which is within the range supported by a systemic arterio-venous 
pressure gradient. At its rated flow of 2.0 L/min, the M-Lung had a pressure drop of 
106 mmHg, which is well within the range supported by a blood pump. A comparison 
of the simulations in Chapter 2 and experimental pressure drop across the M-Lung 
suggests a fiber bundle permeability of 2.8e-9 m2 for the current M-Lung 
configuration.  
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Chapter 4 
Conclusion 
 
Conclusions 
In conclusion, using CFD and optical flow visualization methods we designed a 
unique hollow fiber membrane lung based on concentric circular blood flow paths 
connected by gates, referred to as the M-Lung. Based on these analyses, the optimal 
M-Lung design was prototyped and tested in vitro in accordance with regulatory 
guidelines. The performance and efficiency of the M-Lung was then compared to 
similarly sized commercially available devices in order to evaluate the effectiveness 
of our design. Based on these studies, it can be concluded that:   
1. The concentric circular blood flow paths connected by gates result in 
increased secondary flow mixing within the M-Lung housing; similar vortex 
formation was observed in both computational and experimental methods. 
2. The circular design minimizes stagnant regions and results in a well 
distributed flow profile. 
3. Increasing the number of gates results in a longer blood path and cumulative 
mixing at the cost of an increased pressure drop and resistance across the 
device.
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4. In an optimized M-Lung housing, the incorporation of the fiber bundle results in a 
significant increase of pressure drop and dampening of secondary flow mixing. 
However, the magnitude of these effects can be minimized by increasing the 
permeability and porosity of the fiber bundle, at the cost of a reduced fiber surface 
area and increased priming volume. 
5. The M-Lung comprises a fiber surface area of 0.28 m2 and priming volume of 47 
mL. 
6. The M-Lung has rated flow of 2 L/min and a CO2 clearance of 200 mL/min at the 
rated blood flow.  
7. The blood-side pressure drop of the M-Lung is <50 mmHg at a blood flow rate of 
1.0 L/min, which is within the range supported by a systemic arterio-venous 
pressure gradient. At its rated flow of 2.0 L/min, the M-Lung had a pressure drop 
of 106 mmHg, which is well within the range supported by a blood pump. 
8. The M-Lung has an oxygenation efficiency of 357 mL/min/m2 and CO2 clearance 
efficiency that is more than 2 times that of the Novalung iLA (a commercial lung 
designed for CO2 clearance). In comparison with similarly sized commercial 
devices, the M-Lung uniquely maintains one of the highest efficiencies for both 
oxygen and CO2 transfer. 
 
This M-Lung design meets the functional requirements for providing systemic CO2 
removal support in adults as well as total respiratory support for infants and small 
children; in addition to sufficient gas transfer, it comprises a low priming volume, 
allowing for minimal hemodilution and rapid transit time. The rapid transit time at rated 
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flow and the absence of corners where blood can stagnate should minimize 
thrombogenicity. Furthermore, given its compact size, controllable resistance, and 
potential for low thrombogenicity, the M-Lung has potential for providing long-term 
ambulatory respiratory support, in arterio-venous mode for clearance of CO2 for patients 
with end-stage COPD or pulmonary artery to left atrium mode for total lung support. 
 
Future Work 
Future work will evaluate the performance of a clinical M-Lung in an in vivo model to 
further assess its biocompatibility and chronic performance. Using a disease animal 
model, the chronic performance and efficacy of the M-Lung could be evaluated in 
treating the pathophysiology of end-stage lung disease.  
 
Future studies will also investigate the incorporation of antithrombogenic materials such 
as nitric oxide (NO), which minimizes platelet adhesion and activation, coupled with 
argatroban, which is a direct thrombin inhibitor, in the M-Lung housing and sweep gas in 
an effort to eliminate systemic anticoagulation.  
 
The M-Lung design could be scaled up to achieve total adult respiratory support. Scaling 
up to adult size devices will be done with a return to CFD and PIV to optimize the 
properties of a device with a 5 L/min rated flow, pressure drop <60 mmHg at rated flow, 
and CO2 transfer 2 times oxygen transfer at rated flow. We expect that this will require 
0.6 to 0.8 m2 of gas transfer surface, in contrast with current adult devices, which 
comprise 1.5-1.8 m2.  
